David E. Parkin

TL;DR: The comparable efficacy, favorable safety profile, and convenient dosing support the role of PLD as a valuable treatment option in patients with epithelial ovarian carcinoma that recurred after or didn't respond to first-line, platinum-based chemotherapy.

TL;DR: In this article, the authors compared the combination of docetaxel-carboplatin and paclitaxel carboplatin as first-line chemotherapy for stage Ic-IV epithelial ovarian or primary peritoneal cancer.

TL;DR: Docetaxe-carboplatin appears to be similar to paclitaxel- carboplatin in terms of progression-free survival and response, although longer follow-up is required for a definitive statement on survival.

TL;DR: DWI has potential to provide a surrogate biomarker of treatment response in advanced cervical cancers and offers an early and reproducible indication of tumour response which may ultimately allow the development of individualised regimens.

TL;DR: Various new imaging techniques, such as diffusion-weighted MRI, dynamic contrast-enhanced MRI, magnetic resonance spectroscopy, and 18-fluorodeoxyglucose-PET as early response indicators are described to highlight the current clinical awareness of their use.